CURRICULUM VITAE



Name: POCARD. First name : Marc
marc.pocard@gmail.com
Phone: + 33 610 372 719
N° ORCID : 0000-0002-4793-0008

RPPS : **10000604529**

Professor of Digestive Surgery at Université Paris Cité
Surgery: Digestive Department Pitié Salpêtrière Hospital - 75013 Paris
Research: NABI (Nanomédecine, Biologie Extracellulaire, Intégratome et Innovations en santé) CNRS UMR8175, INSERM U1334, Saints-Pères, Paris

September 23, 2026

Education and training:

. Fellow digestive surgery 1989 – 1996 : Paris University 5, 7 and 13 – Surgeon MD. 1996
. Research fellow St Mark's Hospital London UK 1998
. PhD. Cancer biology 1996 - 1998 Curie Institute Paris.
. Professor of Digestive Surgery at Paris 7 University France 2006.
. MBA: School of Management for Hospital Physicians (EMAMH) 2016

Representative Careers:

- Surgeon at Gustave Roussy – Anti Cancer center – Villejuif France 2001-2005
- Abdominal oncologic surgeon at Lariboisière Hospital – Paris France - 2006
- Director Research Unit ART: Angiogenesis and Translational Research INSERM – 2009-2013
- Editor in chief – Journal of Visceral Surgery – 2011
- Director Research Unit CART: Carcinomatosis Angiogenesis and Translational Research INSERM / Paris 7 University – 2014-2018
- Head of Digestive and Oncologic Surgical department at Lariboisière Hospital – 2014- 2018
- President of the ISSPP International Society for the Study of Pleura and Peritoneum – 2018
- Director Research Unit CAP Paris-Tech: Carcinomatosis Peritoneal Paris Technology INSERM / Université de Paris – 2019 - 2024

Inserm
Institut national de la santé et de la recherche médicale

ISSPP

Université Paris Cité

Specialty & Present Interest:

. Surgical resection of carcinomatosis and intraperitoneal chemotherapy – HIPEC – PIPAC: education, organization, practice and clinical research – 1500 surgery performed
. Peritoneal disease biology: primary rare tumors (pseudomyxoma and mesothelioma), secondary peritoneal metastasis of digestive and ovarian cancer
. Specific subject of interest:

- Evaluation of the exposome for carcinomatosis
- prophylaxis of peritoneal carcinomatosis using intra peritoneal specific drugs
- New technology for peritoneal surgery and early detection of peritoneal carcinomatosis

Representative papers: H index 78 - 10530 Citations – 521 papers on Pubmed

Recent publications

- We validated that in case of incidental appendiceal ruptured adenocarcinoma, cytoreductive surgery and HIPEC can decrease the rate of carcinomatosis recurrence.

Correction: Appendiceal Adenocarcinoma Discovered During Acute Perforated Appendicitis: A Potential Contribution of Prophylactic CRS and HIPEC-A French BIGRENAPE Group Study. Leiritz E, Fawaz J, Sourrouille I, Kepenekian V, Pinson J, Eveno C, Tidadini F, Clément E, Morel Y, Dazza M, Guilloit JM, Marchal F, Glehen O, Pocard M; French BIGRENAPE Group. Ann Surg Oncol. 2026 Mar;33(3):1980.

- Analysis of the omentum of patients who have undergone gastrectomy for cancer has identified environmental pollutants stored in this tissue. These pollutants may activate a particular carcinogenesis pathway via AHR, which may explain the increase in gastric cancer with the presence of independent cells.

Detection of Persistent Organic Pollutants in Omental Adipose Tissue from Patients with Diffuse-Gastric Cancer: A Pilot Study. Perrot-Applanat M, Pimpie C, Cano-Sancho G, Antignac JP, Pocard M. Cancers (Basel). 2021;13(19):4874.

- The onset of peritoneal carcinosis can be prevented by injecting intraperitoneal chemotherapy with a thermo-gel delivery system.

First preclinical evaluation of a thermogel delivering mitomycin C: sustained local release with preserved surgical safety in a large animal model. Mouawad C, Thouvenin A, Rozenbaum P, Pimpie C, Kaci R, Kemmel V, Eveno C, Boudy V, Mignet N, Pocard M. Eur J Surg Oncol. 2026 Mar 27;52(5):111777.

Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model. Seguin J, Pimpie C, Roy P, Al Sabbagh C, Pocard M, Mignet N, Boudy V. Eur J Pharm Biopharm. 2021 Dec;169:37-43.

- Tumor cell implantation, one of the initial elements in the genesis of peritoneal carcinosis, is linked to exposure to fibrin, as are immune changes in the microenvironment.

Injured tissues favor cancer cell implantation via fibrin deposits on scar zones. Al Dybiat I, Mirshahi S, Belalou M, Abdelhamid D, Shah S, Ullah M, Soria J, Pocard M, Mirshahi M. Neoplasia. 2020 Dec;22(12):809-819.

Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1. Ullah M, Aoudjeghout W, Pimpie C, Pocard M, Mirshahi M. Cancers (Basel). 2020 Sep 18;12(9):2661.

- Drug delivery of therapy to the peritoneum can use: charged microvesicles, hyperpressure droplets (PIPAC) or collagen gel.

Immune Reprogramming Precision Photodynamic Therapy of Peritoneal Metastasis by Scalable Stem-Cell-Derived Extracellular Vesicles. Pinto A, Marangon I, Méreaux J, Nicolás-Boluda A, Lavieu G, Wilhelm C, Sarda-Mantel L, Silva AKA, Pocard M, Gazeau F. ACS Nano. 2021 Feb 23;15(2):3251-3263.

Experimental pharmacokinetics evaluation of chemotherapy delivery by **PIPAC** for colon cancer: first evidence for efficacy. Eveno C, Haidara A, Ali I, Pimpie C, Mirshahi M, Pocard M. Pleura Peritoneum. 2017 Jun 1;2(2):103-109.